Fairvalue-Calculator Fairvalue-Calculator
EN DE

JW (Cayman) Therapeutics Co (JWCTF) Fair Value & Analysis

Healthcare · US · Market cap $98.9M

Price$0.2375
Fair Value$1.22
Upside+413.7%
Quality95/100
Evidence: Low Range $0.8000 – $1.52

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

JW (Cayman) Therapeutics Co (JWCTF) currently trades at $0.2375, while our model-based Fair Value estimate is $1.22 — implying the stock looks roughly 413.7% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People's Republic of China. The company offers cell-based immunotherapies, including CAR-T treatment, a treatment method that uses human immune cells to fight cancer. It offers Carteyva, JWCAR201, and JWCAR239 for the treatment of hematological malignancies, advanced relmacabtagene autoleucel injection ("relma-cel") as a potential treatment for systemic lupus erythematosus ("SLE"), and progressed development of products for the treatment of solid tumors, as well as systemic lupus erythematosus (SLE), a chronic autoimmune disease. The company's products pipeline includes JWCAR129, a chimeric antigen receptor (CAR) construct therapy for use in the treatment of multiple myeloma; and JWCAR201, a dual targeting autologous CAR T-cell therapy for use in the treatment of B-cell malignancies and autoimmune disea…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is JW (Cayman) Therapeutics Co (JWCTF) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $1.22 versus a price of $0.2375 — about +414% (undervalued). Model-based estimate, not financial advice.
What is the fair value of JWCTF?
Our 21-model fair value for JW (Cayman) Therapeutics Co is $1.22 (as of Jun 25, 2026), built from audited fundamentals. The current price is $0.2375.
What is the quality score of JWCTF?
JW (Cayman) Therapeutics Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.